
Emmanuel J. Favaloro, PhD, FFSc (RCPA)1

1 Department of Haematology, Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia

Welcome to the start of another year with Seminars in Thrombosis & Hemostasis (STH), this being my 13th year anniversary as Editor in Chief. As always, I sincerely wish to thank again all the contributors to STH over the years, as well as Guest Editors for past issues, and of course the current and past Editorial team. There has been no major overhaul of the editorial team at the time of writing, although some adjustments will continue to occur over the coming years.

I also take this opportunity to once again thank the journal production team at Thieme Medical Publishers for their high production standards and for facilitating both the print and online issues of the journal.

This Editorial also represents the time that we reflect on our journal’s impact factor, which for 2019 was 2.892, and thus it represents a significant decrease from our 2018 impact factor of 3.401. Although somewhat disappointed with this, I would also like to note that a significant decrease in impact factor was seen with most of the journals publishing in the thrombosis and hemostasis field (Fig. 1). As typical for this yearly editorial, I also assessed the trends for self-citations, and this reflects positively for recent data (Fig. 2). In any case, the impact factor is only one of the several markers of the journal “quality” that we should consider, and the limitations of any of the individual markers (including the impact factor) as a “quality” indicator, have previously been discussed.1,2

Like I also do annually, now, the highest cited (2017/2018 published) contributions3–34 from this journal are also listed in Table 1 for the potential interest of the readership and contributing authors. These contributions identify those publications that are mostly contributing to the 2019 impact factor, and each were cited five or more times in the literature in 2019. For those interested, the current listing can be

---

Fig. 1  More “falls” than “rises” in 2019 impact factors among eight journals publishing in thrombosis and hemostasis.

Fig. 2  Percentage of self-citations for Seminars in Thrombosis & Hemostasis in recent years—aiming for less.

---

Address for correspondence
Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales 2145, Australia (e-mail: emmanuel.favaloro@health.nsw.gov.au).

Issue Theme Editorial Compilation IX; Guest Editors: Emmanuel J. Favaloro, PhD, FFSc (RCPA) and Giuseppe Lippi, MD.

© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc., 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

ISSN 0094-6176.
Table 1 Top 2019-cited papers, as published in 2017/2018a

<table>
<thead>
<tr>
<th>Rank</th>
<th>Paper Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>The role of plasminogen activator inhibitor type-1 in fibrosis.</td>
<td>Flevaris P, Vaughan D. Semin Thromb Hemost 2017;43(2):169–177</td>
</tr>
<tr>
<td>8</td>
<td>Plasminogen at the nexus of fibrinolysis, inflammation, and complement.</td>
<td>Foley JH. Semin Thromb Hemost 2017;43(2):135–142</td>
</tr>
<tr>
<td>21</td>
<td>tPA modulation of the blood-brain barrier: a unifying explanation for the pleiotropic effects of tPA in the CNS.</td>
<td>Fredriksson L, Lawrence DA, Medcalf RL. Semin Thromb Hemost 2017;43(2):154–168</td>
</tr>
<tr>
<td>25</td>
<td>To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin?</td>
<td>Kell DB, Pretorius E. Semin Thromb Hemost 2018;44(3):224–238</td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>

*aCited five or more times in 2019. Thus, contributing most to the STH 2019 impact factor.

compared with the most recently published top downloaded article listings from Seminars in Thrombosis & Hemostasis, the basis of the Eberhard F. Mammen “Most Popular” awards.35–39 Accordingly, I would like to thank all the contributors, guest editors, and the editorial team for bringing us the content that makes Seminars in Thrombosis & Hemostasis.

Several papers that I will highlight in particular: (a) the paper by the team of Kitchen, Tiefenbacher, and Gosselin was not only the most cited paper according to — Table 1, but was also awarded one of the 2019 Most Popular awards37; (b) the highly cited paper by Russo and colleagues14 was also awarded one of the 2020 Most Popular awards39; (c) the highly cited paper by Schreiber and colleagues16 was also awarded one of the 2020 Most Popular awards,39 as well as being authored by a recipient of a previous 2016 Young Investigator awardee; (d) the highly cited paper by Lippi and colleagues18 was also awarded one of the 2020 Most Popular awards39; (e) the highly cited paper by Kell and Pretorius27 was also awarded one of the 2019 Most Popular awards.37

Several issues of the journal are also worthy to be highlighted as most of them contributed to the 2019 impact factor. The seven most highly contributing issues,40–46 both in terms of total and average impact factor contributions, were:

3. Recent Advances in Thrombosis and Hemostasis—Part III. Guest Editor: Sam Schulman.

Finally, a short note to confirm that we, like always, will continue to develop plans for the future content of this journal, and we are confident that Seminars would continue to bring its readers the high-quality journal that is expected of us. Currently confirmed topics for issues that we plan to publish over the next 12 or so months are listed in — Table 2. At the same time, we recognize the need to retain some

Table 2 Current planned topics for future issues of Seminars in Thrombosis & Hemostasis include:

- Editorial compilations (continuing series)
- Recent advances in thrombosis and hemostasis (continuing series)
- Maintaining hemostasis and preventing thrombosis in COVID-19 (continuing series)
- Innovations in thrombosis and hemostasis part II: focus on tests and assays
- Hemostatic and nonhemostatic effects of heparan sulfate proteoglycans (HSPG).
- Cardiovascular and thromboembolic diseases in oncology: novel aspects and revisited issues.
- Personalized approaches to bleeding and thrombotic disorders.
- Altered fibrinolysis: clinical impact and diagnostic challenges.

flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises. Notably, coronavirus disease 2019 (COVID-19) continues to create havoc for all of us, and this pandemic has led us to create a continuing series of issues specifically focused on thrombosis and hemostasis in COVID-19. Irrespective, we look forward to another interesting year of reading in 2021.

Conflict of Interest
None declared.

References
5 Flevaris P, Vaughan D. The role of plasminogen activator inhibitor type-1 in fibrosis. Semin Thromb Hemost 2017;43(02):169–177
10 Foley JH. Plasminogen: at the nexus of fibrinolysis, inflammation, and complement. Semin Thromb Hemost 2017;43(02):135–142
23 Fredriksson L, Lawrence DA, Medcalf RL. tPA modulation of the blood-brain barrier: a unifying explanation for the pleiotropic effects of tPA in the CNS. Semin Thromb Hemost 2017;43(02):154–168
27 Kell DB, Pretorius E. To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin? Semin Thromb Hemost 2018;44(03):224–238
Favaloro EJ. 2019 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards. Semin Thromb Hemost 2020; 46(02):105–113


Schulman S. Recent advances in thrombosis and hemostasis—Part III. Semin Thromb Hemost 2018; 44(04):312–314


